Raising the standards of care
With our proprietary focused heat technology platforms, our treatments are minimally invasive, non-toxic. We are leading the way in new developments in cancerous and non-cancerous treatments for breast disease and BPH.
Read MoreImprove the Outcome
Our goal is to improve outcomes and standards of care in cancerous and non-cancerous treatments. Clinical studies have demonstrated that when used in conjunction with chemotherapy for breast cancer, Medifocus’ patented APA system can significantly increase tumor shrinkage by 50 percent. For BPH, the Prolieve system has shown it can significantly decrease the American Urological Association (AUA) symptom scores.
Read MoreMedical Professionals
Medifocus develops and commercializes minimally invasive treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”). The Company owns two technology platforms with comprehensive US and international patent protection: 1. The “Endo-thermotherapy Platform”, and 2. The “Adaptive Phased Array Microwave Focusing Platform”. The Company has received regulatory approvals to complete the APA 1000’s pivotal Phase-III clinical trials, the final step before marketing approval. The U.S....
Read MoreMinimally Invasive
Our focused heat treatment systems are designed with patients’ needs and comfort in mind. They are minimally invasive, nontoxic, and have little to no side effects.
Read MoreBetter Cancer Treatment Options
The future goal for Medifocus is to further expand the capabilities of its APA microwave focusing technology platform to develop and commercialize other focused heat treatment systems for surface, subsurface and deep seated tumors anywhere in the body.
Read More